MORPHOSYS AG O.N. news, videos and press releases
For more news please use our advanced search feature.
MORPHOSYS AG O.N. - More news...
MORPHOSYS AG O.N. - More news...
- EQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
- Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
- EQS-News: MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
- EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
- EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
- EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
- EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
- Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
- EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
- EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
- MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
- EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
- MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
- EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
- Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
- EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
- EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
- EQS-News: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
- EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
- EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
- EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
- EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
- EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
- EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
